Insilico Medicine has entered a strategic collaboration with SK Biopharmaceuticals to accelerate the discovery and development of novel therapies for neuroimmune disorders affecting the central nervous system (CNS). This partnership, which could generate up to $2.5 billion for Insilico, leverages the company’s artificial intelligence platform to identify and optimize drug candidates, while SK Biopharmaceuticals will drive late-stage development and commercialization.
Insilico will apply its Pharma.AI platform, which integrates target validation, generative chemistry, and molecule optimization, to design and craft drug candidates based on targets provided by SK. The collaboration focuses not just on early-stage discovery but on delivering viable drug molecules, with Insilico advancing candidates through preclinical stages before handing them over to SK. This approach reflects SK’s confidence in AI’s potential to streamline drug development and boost efficiency.
As a global biotechnology company headquartered in Seongnam, South Korea, SK Biopharmaceuticals specializes in the development and commercialization of treatments for CNS conditions. The company’s notable achievement includes the independent approval and launch of the epilepsy drug Xcopri® (cenobamate) in the United States, marking a milestone in Korean pharmaceutical innovation. This new alliance aims to broaden SK’s CNS portfolio beyond epilepsy into neuroimmune diseases, an area of growing clinical interest.
SK Biopharmaceuticals’ leadership emphasized the collaboration’s scalability, viewing it as a platform for continuous growth and future drug discovery endeavors. By combining Insilico’s AI-driven discovery tools with SK’s clinical development and U.S. market expertise, both companies intend to accelerate the availability of innovative CNS treatments for patients worldwide.